Comparing Emmaus Life Sciences (NASDAQ:EMMA) & Davita (NASDAQ:DVA)

Emmaus Life Sciences (NASDAQ:EMMA) and Davita (NYSE:DVA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Emmaus Life Sciences and Davita, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Emmaus Life Sciences 0 0 0 0 N/A
Davita 0 6 3 0 2.33

Davita has a consensus price target of $64.74, indicating a potential upside of 11.97%. Given Davita’s higher possible upside, analysts clearly believe Davita is more favorable than Emmaus Life Sciences.

Profitability

This table compares Emmaus Life Sciences and Davita’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Emmaus Life Sciences -561.61% -467.46% -216.02%
Davita 1.21% 14.67% 2.95%

Valuation and Earnings

This table compares Emmaus Life Sciences and Davita’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Emmaus Life Sciences $1.32 million 117.96 -$9.59 million ($11.16) -0.29
Davita $11.40 billion 0.81 $159.39 million $3.57 16.20

Davita has higher revenue and earnings than Emmaus Life Sciences. Emmaus Life Sciences is trading at a lower price-to-earnings ratio than Davita, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Emmaus Life Sciences has a beta of 2.86, suggesting that its share price is 186% more volatile than the S&P 500. Comparatively, Davita has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Insider & Institutional Ownership

0.1% of Emmaus Life Sciences shares are owned by institutional investors. Comparatively, 89.6% of Davita shares are owned by institutional investors. 36.9% of Emmaus Life Sciences shares are owned by company insiders. Comparatively, 0.7% of Davita shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Davita beats Emmaus Life Sciences on 10 of the 13 factors compared between the two stocks.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.

About Davita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2018, it provided dialysis and administrative services in the United States through a network of 2,664 outpatient dialysis centers serving approximately 202,700 patients; and operated 241 outpatient dialysis centers located in 9 countries outside of the United States serving approximately 25,000 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.